← All trials
NCT04618497
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2020
- Primary completion
- Nov 21, 2020
- Completion date
- Nov 21, 2020
- First posted
- Nov 6, 2020
- Last posted
- Dec 8, 2020
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of Hong KongLead sponsor
- Government of Hong KongOverall official - principal investigator
- Government of Hong KongReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.